The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 10, 2003, Pages 1283-1290

  Sheu, B S ^a,b   Huang, J J ^a   Yang, H B ^a   Huang, A H ^a   Wu, J J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMOXICILLIN; BACTERIAL ANTIGEN; CLARITHROMYCIN; CREATININE; LANSOPRAZOLE; METRONIDAZOLE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANTIGEN DETECTION; ARTICLE; BITTER TASTE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TASTE DISORDER; TREATMENT OUTCOME; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 0037944104     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01527.x     Document Type: Article

References (29)

1. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285-91.
2. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
3. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
4. Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? Arch Intern Med 2000; 160: 105-9.
5. Rokkas T, Karameris A, Mavrogeorgis A, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41: 1-4.
6. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Flelicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics: the MACH1 study. Helicobacter 1996; 1: 138-44.
7. Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole-based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95.
8. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
9. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
10. Wang YL, Sheu BS, Huang JJ, Yang HB. Non-invasive stool antigen assay can effectively screen H. pylori infection and assess the success of eradication therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 98-103.
11. Bustillo MD, Tomero JAS, Sanz JC, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998; 79: 55-60.
12. Arancibia A, Drouguett MT, Fuentes G, et al. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol 1982; 20: 447-53.
13. Humbert G, Spyker DA, Fillastre JP, Leroy A. Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 1979; 15: 28-33.
14. Geller RJ, Chevalier RL, Spyker DA. Acute amoxicillin nephrotoxicity following an overdose. J Toxicol Clin Toxicol 1986; 24: 175-82.
15. Jones DP, Gaber L, Nilsson GR, Brewer ED, Stapleton FB. Acute renal failure following amoxicillin overdose. Clin Pediatr 1993; 32: 735-9.
16. Belko J, Urueta G, Emre U. Amoxicillin overdose manifested by hematuria and acute renal failure. Pediatr Infect Dis J 1995; 14: 917-9.
17. Kappel J, Calissi P. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. CMAJ 2002; 166: 473-7.
18. Steinman MA, Steinman TI. Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 27: 143-6.
19. Hestin D, Hanesse B, Frimat L, Trechot P, Netter P, Kessler M. Metronidazole-associated hepatotoxicity in a hemodialyzed patient. Nephron 1994; 68: 286.
20. 13C-urea breath test is mandatory to detect H. pylori infection of patients after triple therapy. Dig Dis Sci 2000; 45: 1330-6.
21. 13C-urea breath test is not as accurate as endoscopy to detect H. pylori infection for patients after partial gastrectomy. Gastrointest Endosc 2000; 51: 670-5.
22. Sheu SM, Sheu BS, Yang HB, Lai C, Chu TC, Wu JJ. The presence of iceA1 but not cagA, cagC, cagE, cagF, cagN, cagT, or orf13 genes of Helicobacter pylori is associated with a more severe gastric inflammation in Taiwanese. J Formosan Med Assoc 2002; 101: 18-23.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-8.
25. Davenport A, Shallcross TM, Crabtree JE, Davison AM, Will EJ, Heatley RV. Prevalence of Helicobacter pylori in patients with end-stage renal failure and renal transplant recipients. Nephron 1991; 59: 597-601.
26. Offerhaus GJA, Kreuning J, Valentijn RM, et al. Cambylobacter pylori: prevalence and significance in patients with chronic renal failure. Clin Nephrol 1989; 32: 239-41.
27. Gladziwa U, Haase G, Handt S. Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transplant 1993; 8: 301-6.
28. Sheu BS, Huang JJ. Helicobacter pylori infection in patients with uremia [Editorial]. Int J Artif Organs 2001; 24: 669-70.
29. Mak SK, Loo CK, Wong AMC, et al. Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure. Am J Kidney Dis 2002; 40: 576-81.